Feasibility Study of MRI-Guided Stereotactic Ablative Radiotherapy for Abdominal and Lung Tumors

What this Trial Is About

Researchers are studying whether highly focused and intense radiation can be safely delivered to tumors in the abdominal area or chest using a high-strength MRI-guided radiotherapy machine called an MR-Linac. This approach aims to improve treatment by limiting radiation exposure to surrounding organs while providing better imaging and real-time treatment adaptation compared to standard x-ray guided methods. The study is observational and intends to compare patient experiences and outcomes with those receiving standard treatments. The study involves using MRI-guided stereotactic ablative radiotherapy SABR for patients with small, localized tumors in the thorax or abdomen. This method offers superior imaging during treatment, real-time adjustments, and the possibility to collect additional research images without extra radiation. Participants will receive treatment following established guidelines for abdominal or central lung SABR. Researchers will assess if MRI guidance improves treatment delivery and patient outcomes compared to standard care. Participants will be monitored to see if over 85% complete their radiotherapy as planned within 30 months. The study will collect data on patient experiences, tumor and tissue changes during treatment, and follow-up information for at least one year. Safety is carefully monitored, especially regarding MRI compatibility. The total participation time varies, with follow-up assessments to evaluate treatment success and patient well-being after therapy.

A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)